Table 13.
Drugs with Phase 3 Studies in the Treatment of NASH
| Active ingredient | Abbreviation | Name of the study | The company name | Mechanism of action |
|---|---|---|---|---|
| Obeticholic acid | OCA (Ocaliva) | REGENERATE | INTERCEPT | FXR agonist |
| Elafibranor | GFT-505 | GOLDEN-505 | GENFIT | PPAR-α/δ agonist |
| RESOLVE-IT | ||||
| Cenicriviroc | CVC | AURORA | ALLERGAN | CCR2/CCR5 inhibitor |
| Selonsertib | SEL | STELLAR 3 | GILEAD | ASK1 inhibitor |
| GS-4997 | STELLAR 4 | |||
| Aramchol | ARMOR | GALMED | SCD1 inhibitor | |
| Semaglutide | ESSENCE | NOVO NORDISK | GLP-1 receptor agonist | |
| Resmetirom | MGL-3196 | MAESTRO-NASH | MADRIGAL | THR-β agonist |
| Belapectin | GR-MD-02 | NAVIGATE | GALECTIN THERA PEUTICS | Galectin-3 inhibitor |
FXR: Farnesoid X receptor; PPAR: Peroxisome proliferator-activated receptor; CCR2, CCR5: C chemokine receptor type 2 and 5; ASK1: Apoptosis signal-regulating kinase 1; SCD1: Stearoyl -coenzyme A desaturase -1; GLP-1: Glucagon-like peptide-1; THR-β: Thyroid-hormone receptor-beta.